pharmaceutical industry

Heart Drug Spotlights Troubling Trends In Drug Marketing

A company is marketing a drug intended as a preventive for people at risk for heart disease with stunning statistics but has not yet released details of its study.

At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions.

Subscribe to pharmaceutical industry